Barclays PLC is grappling with a serious securities investigation led by Rosen Law Firm, following allegations of misleading business information that could impact shareholders significantly. This scrutiny comes as Barclays reports a staggering exposure of £600 million ($809.70 million) to Market Financial Solutions Ltd, a UK mortgage provider.
The fallout from these revelations has been swift, with Barclays’ American Depositary Shares (ADS) plummeting 3.99% on February 27, 2026, and a further decline of 2.3% on March 2, 2026. The bank’s financial health is under severe strain as it faces losses of up to £500 million on loans to Market Financial Solutions and over £110 million on loans to Tricolor, a US subprime auto parts provider.
Barclays’ CEO, CS Venkatakrishnan, expressed regret over these losses, indicating a shift in strategy as the bank pulls back on asset-backed loans. This decision marks a significant change from its previous interest in expanding its securitization business, a strategy unveiled back in February 2024.
In addition to these challenges, Barclays has also cut its price target on Molson Coors from $47 to $40, maintaining an Underweight rating. This adjustment reflects concerns over sustained cost headwinds and volume erosion, which are expected to compress earnings multiples for the brewer throughout 2026.
Molson Coors has already seen its shares decline nearly 2.00% over the past week and more than 13% year-to-date, further complicating Barclays’ outlook.
As the investigation unfolds, shareholders who purchased Barclays securities may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement. Details remain unconfirmed regarding the full implications of the investigation and the potential financial repercussions for Barclays.
The situation remains fluid, with further developments expected as Rosen Law Firm continues its inquiry. Investors and stakeholders are closely monitoring the bank’s next moves in response to these significant challenges.